Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

Results from the Mariposa study found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced lung ...

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options ...

Why Many Lung Cancer Patients Who Have Never Smoked Have Worse Outcomes June 13, 2024 — The reason why targeted treatment for non-small cell lung cancer fails to work for some patients ...

Innovent Biologics Inc. (IVBXF.OB) and Jiangsu Aosaikang Pharmaceutical Co. Ltd. or ASK Pharm announced that China's National Medical ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab ...

Ultrasensitive ctDNA detection with NeXT Personal shows 81% sensitivity in early-stage lung adenocarcinoma, improving ...